First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

Background The antibody-drug conjugate PF-06263507 targets the cell-surface, tumor-associated antigen 5T4 and consists of a humanized IgG1 conjugated to the microtubule-disrupting agent monomethylauristatin-F by a non-cleavable maleimidocaproyl linker. In this first-in-human, dose-finding trial (NCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Geoffrey I., Vaishampayan, Ulka N., LoRusso, Patricia, Barton, Jeremy, Hua, Steven, Reich, Steven D., Shazer, Ronald, Taylor, Carrie T., Xuan, Dawei, Borghaei, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418317/
https://www.ncbi.nlm.nih.gov/pubmed/28070718
http://dx.doi.org/10.1007/s10637-016-0419-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418317/
https://www.ncbi.nlm.nih.gov/pubmed/28070718
http://dx.doi.org/10.1007/s10637-016-0419-7

Ejemplares similares